Trump tells drugmakers to ‘justify the success’ of Covid meds after FDA limits vaccine approval

Trump tells drugmakers to ‘justify the success’ of Covid meds after FDA limits vaccine approval


U.S. President Donald Trump in the Cabinet Room of the White House on Aug. 26, 2025 in Washington, D.C.

Chip Somodevilla | Getty Images

President Donald Trump on Monday called on pharmaceutical companies to “justify the success” of their Covid drugs days after the Food and Drug Administration set new limits on who can receive vaccines for the virus.

“It is very important that the Drug Companies justify the success of their various Covid Drugs. Many people think they are a miracle that saved Millions of lives. Others disagree!” Trump wrote in a Truth Social post.

The FDA on Wednesday approved the latest round of Covid vaccines, but only for people at higher risk of severe illness.

The president’s comments also come days after he fired Centers for Disease Control and Prevention Director Susan Monarez after she refused to resign. Four other top health officials at the CDC also announced they were quitting the agency last week, including Demetre Daskalakis, director of the National Center for Immunization and Respiratory Diseases.

“With CDC being ripped apart over this question, I want the answer, and I want it NOW,” Trump said in the post.

“I have been shown information from Pfizer, and others, that is extraordinary, but they never seem to show those results to the public. Why not???” the president wrote.

Pfizer did not immediately respond to CNBC’s request for comment.

The leadership upheaval at the CDC follows a series of measures by Health and Human Services Secretary Robert F. Kennedy Jr. to overhaul federal health agencies and change U.S. immunization policies. He has instituted mass firings, gutted a key government vaccine panel and canceled studies on mRNA shot technology.

Trump urged drug companies to be more transparent about their results to “clear up this MESS,” writing that drugmakers “let everyone rip themselves apart, including Bobby Kennedy Jr. and CDC, trying to figure out the success or failure of the Drug Companies Covid work.”

Trump in the post also continued to tout Operation Warp Speed, his first administration’s pandemic vaccine effort launched in May 2020 to accelerate the development, manufacturing and distribution of Covid vaccines and therapeutics.

Yet Kennedy — a prominent vaccine skeptic — has downplayed the efficacy of vaccinations.

In a guest essay published in the New York Times on Monday, a group of nine former directors and acting directors of the CDC said Kennedy is “endangering” Americans’ health.

“What [Kennedy] has done to the C.D.C. and to our nation’s public health system over the past several months — culminating in his decision to fire Dr. Susan Monarez as C.D.C. director days ago — is unlike anything we have ever seen at the agency, and unlike anything our country has ever experienced,” the group wrote.

“We are worried about the wide-ranging impact that all these decisions will have on America’s health security,” they said.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More